Preview

User

Not a user? Register with this site Forgot your password?

Cardiovascular Therapy and Prevention

Advanced search

Dyslipidemia in the Russian Federation: population data, associations with risk factors

https://doi.org/10.15829/1728-8800-2023-3791

EDN: DGYJLA

Abstract

Aim. To study the prevalence of dyslipidemias and their association with various risk factors in the Russian population of men and women aged 35-74 years in 2020-2022.

Material and methods. This work was carried out as part of the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation-3 (ESSE-RF3) study. The sample included 28731 men and women aged 35-74 years living in 15 Russian regions. Hypercholesterolemia (HC) was diagnosed with total cholesterol (TC) ≥5,0 mmol/l, while elevated low-density lipoprotein cholesterol (LDL-C) was considered ≥3,0 mmol/l, hypertriglyceridemia — with triglyceride levels ≥1,7 mmol/l, reduced high-density lipoprotein cholesterol (HDL-C) <1,0 mmol/l in men and <1,2 mmol/l in women. Associations were assessed using logistic regression after adjustment for socio-demographic characteristics, drinking status, presence of hypertension (HTN) and stroke.

Results. The prevalence of hypertriglyceridemia in the Russian Federation in 2020-2022 was 58,8%, hypertriglyceridemia — 32,2%. The incidence of lipid-lowering therapy increased with age from 1% in the group of 35-44 years to 16% in the group of 65-74 years. On average, only 7,6% of study participants received lipid-lowering therapy. Significant associations of HC with HTN, obesity and alcohol abuse were identified. Similar results were obtained for elevated LDL-C levels, with the exception of alcohol abuse. In turn, a reduced HDL-C level was significantly associated with the lack of higher education, marriage, physical activity, smoking and the presence of diseases.

Conclusion. The prevalence of lipid disorders in the Russian Federation in 2020-2022 remained at a high level. These disorders occurred more often in women, and they were better informed about their cholesterol levels and more often received lipid-lowering therapy. HTN, obesity, and some behavioral and social risk factors were associated with dyslipidemia.

About the Authors

O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


A. E. Imaeva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


V. A. Kutsenko
National Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State University
Russian Federation

Moscow


A. V. Kapustina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


Yu. A. Balanova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


S. A. Maksimov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


G. A. Muromtseva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


M. B. Kotova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


N. S. Karamnova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


S. E. Evstifeeva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


O. A. Litinskaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


M. S. Pokrovskaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


N. A. Imaeva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


E. M. Filichkina
National Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State University
Russian Federation

Moscow


O. E. Ivlev
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


G. E. Svinin
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


L. I. Gomanova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


Yu. V. Doludin
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


I. A. Efimova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


A. L. Borisova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


B. M. Nazarov
City Polyclinic № 109
Russian Federation

Moscow


E. B. Yarovaya
National Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State University
Russian Federation

Moscow


T. V. Repkina
Regional Center for Public Health and Medical Prevention
Russian Federation

Barnaul


T. O. Gonoshilova
Regional Center for Public Health and Medical Prevention
Russian Federation

Barnaul


A. V. Kudryavtsev
Northern State Medical University
Russian Federation

Arkhangelsk


N. I. Belova
Northern State Medical University
Russian Federation

Arkhangelsk


L. L. Shagrov
Northern State Medical University
Russian Federation

Arkhangelsk


M. A. Samotrueva
Astrakhan State Medical University
Russian Federation

Astrakhan


A. L. Yasenyavskaya
Astrakhan State Medical University
Russian Federation

Astrakhan


E. N. Chernysheva
Astrakhan State Medical University
Russian Federation

Astrakhan


S. V. Glukhovskaya
Sverdlovsk Regional Medical College
Russian Federation

Ekaterinburg


I. A. Levina
Sverdlovsk Regional Medical College
Russian Federation

Ekaterinburg


E. A. Shirshova
Sverdlovsk Regional Medical College
Russian Federation

Ekaterinburg


E. B. Dorzhieva
Boyanov Center for Public Health and Medical Prevention
Russian Federation

Ulan-Ude


E. Z. Urbanova
Boyanov Center for Public Health and Medical Prevention

Ulan-Ude


N. Yu. Borovkova
Privolzhsky Research Medical University
Russian Federation

Nizhny Novgorod


V. K. Kurashin
Privolzhsky Research Medical University
Russian Federation

Nizhny Novgorod


A. S. Tokareva
Privolzhsky Research Medical University
Russian Federation

Nizhny Novgorod


Yu. I. Ragino
Research Institute of Internal and Preventive Medicine — branch of the Institute of Cytology and Genetics
Russian Federation

Novosibirsk


G. I. Simonova
Research Institute of Internal and Preventive Medicine — branch of the Institute of Cytology and Genetics
Russian Federation

Novosibirsk


V. S. Shramko
Research Institute of Internal and Preventive Medicine — branch of the Institute of Cytology and Genetics
Russian Federation

Novosibirsk


V. N. Nikulin
Orenburg Regional Center for Public Health and Medical Prevention
Russian Federation

Orenburg


O. R. Aslyamov
Orenburg Regional Center for Public Health and Medical Prevention
Russian Federation

Orenburg


G. V. Khokhlova
Orenburg Regional Center for Public Health and Medical Prevention
Russian Federation

Orenburg


A. V. Solovyova
Tver State Medical University
Russian Federation

Tver


A. A. Rodionov
Tver State Medical University
Russian Federation

Tver


O. V. Kryachkova
Tver State Medical University
Russian Federation

Tver


Yu. Yu. Shamurova
South Ural State Medical University
Russian Federation

Chelyabinsk


I. V. Tantsyreva
South Ural State Medical University
Russian Federation

Chelyabinsk


I. N. Baryshnikova
South Ural State Medical University
Russian Federation

Chelyabinsk


M. G. Ataev
Abusuev Research Institute of Environmental Medicine, Dagestan State Medical University
Russian Federation

Makhachkala


M. O. Radjabov
Abusuev Research Institute of Environmental Medicine, Dagestan State Medical University
Russian Federation

Makhachkala


M. M. Isakhanova
Abusuev Research Institute of Environmental Medicine, Dagestan State Medical University
Russian Federation

Makhachkala


M. A. Umetov
Berbekov Kabardino-Balkarian State University
Russian Federation

Nalchik


L. V. Elgarova
Berbekov Kabardino-Balkarian State University
Russian Federation

Nalchik


I. A. Khakuasheva
Berbekov Kabardino-Balkarian State University
Russian Federation

Nalchik


E. I. Yamashkina
Ogarev Mordovian State University
Russian Federation

Saransk


M. V. Esina
Ogarev Mordovian State University
Russian Federation

Saransk


T. A. Kunyaeva
Ogarev Mordovian State University; Mordovian Republican Central Clinical Hospital
Russian Federation

Saransk


A. M. Nikitina
Republican Center for Public Health and Medical Prevention
Russian Federation

Yakutsk


N. V. Savvina
Ammosov North-Eastern Federal University
Russian Federation

Yakutsk


Yu. E. Spiridonova
Republican Center for Public Health and Medical Prevention
Russian Federation

Yakutsk


E. A. Naumova
Republican Center for Public Health and Medical Prevention, Exercise therapy and Sports Medicine
Russian Federation

Cheboksary


A. A. Keskinov
Center for Strategic Planning and Management of Biomedical Health Risks
Russian Federation

Moscow


V. S. Yudin
Center for Strategic Planning and Management of Biomedical Health Risks
Russian Federation

Moscow


S. M. Yudin
Center for Strategic Planning and Management of Biomedical Health Risks
Russian Federation

Moscow


A. V. Kontsevaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


S. A. Shalnova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Moscow


References

1. Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):139-48.

2. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5:56. doi:10.1038/s41572-019-0106-z.

3. Institute for Health Metrics and Evaluation. Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME. 2018;1-25.

4. Kontsevaya AV, Balanova YuA, Imaeva AE, et al. Economic burden of hypercholesterolemia in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2018;14(3):393-401. (In Russ.) doi:10.20996/1819-6446-2018-14-3-393-401.

5. NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582:73-7. doi:10.1038/s41586-020-2338-1.

6. Vancheri F, Backlund L, Strender LE, et al. Time trends in statin utilisation and coronary mortality in Western European countries. BMJ Open. 2016;6:e010500. doi:10.1136/bmjopen-2015-010500.

7. Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Archives of medical research. 2015;46(5):328-38. doi:10.1016/j.arcmed.2015.06.006.

8. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563-95. doi:10.1161/CIR.0000000000000677.

9. Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375(24):2349-58. doi:10.1056/NEJMoa1605086.

10. Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: results of the ESSE-RF study for the years 2012-2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7. (In Russ.) doi:10.15829/1728-8800-2017-4-62-67.

11. Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Profilakticheskaya Meditsina. 2016;19(1):15‑23. (In Russ.) doi:10.17116/profmed201619115-23.

12. Drapkina OM, Shalnova SA, Imaeva AE, et al. Epidemiology of Cardiovascular Diseases in Regions of Russian Federation. Third survey (ESSE-RF-3). Rationale and study design. Cardiovascular Therapy and Prevention. 2022;21(5):3246. (In Russ.) doi:10.15829/1728-8800-2022-3246.

13. Imaeva AE, Tuaeva EM, Shalnova SA, et al. Coronary heart disease and risk factors in elderly population. Cardiovascular Therapy and Prevention. 2016;15(2):93-9. (In Russ.) doi:10.15829/1728-8800-2016-2-93-99.

14. Li Z, Zhu G, Chen G, et al. Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018. Lipids Health Dis. 2022;21(1):111. doi:10.1186/s12944-022-01721-y.

15. Wang M, Liu M, Li F, et al. Gender heterogeneity in dyslipidemia prevalence, trends with age and associated factors in middle age rural Chinese. Lipids Health Dis. 2020;19(1):135. doi:10.1186/s12944-020-01313-8.

16. Lizcano F, Guzmán G. Estrogen Deficiency and the Origin of Obesity during Menopause. Biomed Res Int. 2014;2014:757461. doi:10.1155/2014/757461.

17. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25(4):563-77. vii. doi:10.1016/j.cger.2009.07.007.

18. Martone AM, Landi F, Petricca L, et al. Prevalence of dyslipidemia and hypercholesterolemia awareness: results from the Lookup 7+ online project. Eur J Public Health. 2022;32(3):402-7. doi:10.1093/eurpub/ckab224.

19. Vartiainen E, Laatikainen T, Tapanainen H, et al. Changes in Serum Cholesterol and Diet in North Karelia and All Finland. Global Heart. 2016;11:179-84. doi:10.1016/j.gheart.2016.04.006.

20. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. doi:10.1016/S0140-6736(04)17018-9.

21. Karamnova NS, Rytova AI, Shvabskaya OB. Associations of eating and drinking habits with cardiovascular disease and diabetes in the adult population: data from the ESSE-RF epidemiological study. Cardiovascular Therapy and Prevention. 2021;20(5):2982. (In Russ.) doi:10.15829/1728-8800-2021-2982.

22. Shalnova SA, Deev AD. High-risk patient characteristics. Results of the OSCAR Study: epidemiological part. Cardiovascular Therapy and Prevention. 2006;5(5):58-63. (In Russ.)

23. Rudkowska I, Jones PJ. Functional foods for the prevention and treatment of cardiovascular diseases: cholesterol and beyond. Expert Rev Cardiovasc Ther. 2007;5(3):477-90. doi:10.1586/14779072.5.3.477.

24. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000. doi:10.1001/jama.2009.1619.

25. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-23. doi:10.1016/S0140-6736(10)60834-3.

26. Manjunath CN, Rawal JR, Irani PM, et al. Atherogenic dyslipidemia. Indian J Endocrinol Metab. 2013;17(6):969-76. doi:10.4103/2230-8210.122600.

27. Chen S, Cheng W. Relationship between lipid profiles and hypertension: a cross-sectional study of 62,957 Chinese adult males. Front Public Health. 2022;10:895499. doi:10.3389/fpubh.2022.895499.

28. Otsuka T, Takada H, Nishiyama Y, et al. Dyslipidemia and the risk of developing hypertension in a working-age male population. J Am Heart Assoc. 2016;5(3):e003053. doi:10.1161/JAHA.115.003053.

29. Zhu J, Zhang Y, Wu Y, et al. Obesity and dyslipidemia in Chinese adults: a cross-sectional study in Shanghai, China. Nutrients. 2022;14(11):2321. doi:10.3390/nu14112321.

30. Stefanović A, Zeljković A, Vekić J, et al. Dyslipidemia in type 2 diabetes mellitus. Arhiv Za Farmaciju. 2019;69(5):338-48. doi:10.5937/arhfarm1905338s.

31. George S, John S, George S, et al. Lipid profile and alcoholism. Int J Adv Med. 2019;6(5):1-8. doi:10.18203/2349-3933.ijam20193595.

32. Kim SK, Kim HC, Shim JS, et al. Effects of cigarette smoking on blood lipids in Korean men: Cardiovascular and Metabolic Diseases Etiology Research Center cohort. Korean J Intern Med. 2020;35(2):369-82. doi:10.3904/kjim.2019.133.

33. Colsoul M-L, Goderniaux N, Onorati S, et al. Changes in biomarkers of endothelial function, oxidative stress, inflammation and lipids after smoking cessation: A cohort study. Eur J Clin Invest. 2023;53:e013996. doi:10.1111/eci.13996.

34. Kodama S, Tanaka S, Saito K, et al. Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol: A Meta-analysis. Arch Intern Med. 2007;167(10):999-1008. doi:10.1001/archinte.167.10.999.

35. Crichton GE, Alkerwi A. Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study. Lipids Health Dis. 2015;14:87. doi: 10.1186/s12944-015-0085-3.

36. Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids Health Dis. 2017;16(1):132. doi:10.1186/s12944-017-0515-5.

37. Woo J, Leung S, Ho S, et al. Influence of educational level and marital status on dietary intake, obesity and other cardiovascular risk factors in a Hong Kong Chinese population. Eur J Clin Nutr. 1999;53:461-7. doi:10.1038/sj.ejcn.160077.


Supplementary files

What is already known about the subject?

  • The results of numerous studies indicate that dyslipidemias make a significant contribution to atherosclerotic cardiovascular diseases and are associated with significant economic damage.
  • Currently, there are no data on the prevalence of dyslipidemia in the Russian Federation, as well as their relationship with cardiovascular risk fac­tors.

What might this study add?

  • The prevalence of hypercholesterolemia in the Russian Federation in 2020-2022 was 58,8%, hyper­triglyceridemia — 32,2%.
  • Women are more informed about their cholesterol levels and are more likely to receive lipid-­lowering therapy compared to men. Although the proportion of persons receiving lipid-­lowering therapy increased with age, it accounted for only 7,6% of the general population.
  • Hypertension, obesity, behavioral and social risk factors were significantly associated with dyslipi­demia.

Review

For citations:

Drapkina O.M., Imaeva A.E., Kutsenko V.A., Kapustina A.V., Balanova Yu.A., Maksimov S.A., Muromtseva G.A., Kotova M.B., Karamnova N.S., Evstifeeva S.E., Litinskaya O.A., Pokrovskaya M.S., Imaeva N.A., Filichkina E.M., Ivlev O.E., Svinin G.E., Gomanova L.I., Doludin Yu.V., Efimova I.A., Borisova A.L., Nazarov B.M., Yarovaya E.B., Repkina T.V., Gonoshilova T.O., Kudryavtsev A.V., Belova N.I., Shagrov L.L., Samotrueva M.A., Yasenyavskaya A.L., Chernysheva E.N., Glukhovskaya S.V., Levina I.A., Shirshova E.A., Dorzhieva E.B., Urbanova E.Z., Borovkova N.Yu., Kurashin V.K., Tokareva A.S., Ragino Yu.I., Simonova G.I., Shramko V.S., Nikulin V.N., Aslyamov O.R., Khokhlova G.V., Solovyova A.V., Rodionov A.A., Kryachkova O.V., Shamurova Yu.Yu., Tantsyreva I.V., Baryshnikova I.N., Ataev M.G., Radjabov M.O., Isakhanova M.M., Umetov M.A., Elgarova L.V., Khakuasheva I.A., Yamashkina E.I., Esina M.V., Kunyaeva T.A., Nikitina A.M., Savvina N.V., Spiridonova Yu.E., Naumova E.A., Keskinov A.A., Yudin V.S., Yudin S.M., Kontsevaya A.V., Shalnova S.A. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3791. EDN: DGYJLA

Views: 2854


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)

101000, Moscow, Petroverigsky per., 10, str. 3
National medical research center for therapy and preventive medicine

Тел: +7 (499) 553 67 78

Editorial office Cardiovascular Therapy and Prevention

Processing of personal data
supported by NEICON (Elpub lab)